The University of the Sunshine Coast will investigate a potential COVID-19 vaccine, delivered by a microarray patch.
USC Clinical Trials has partnered with Vaxxas, developers of the patch, after running a similar study in 2021 for measles and rubella.Vaxxas Chief Technology Officer, Dr Angus Forster, said the study would look into the safety and tolerability of a potential vaccine, using the company’s high-density microarray patch technology.
“We hope to demonstrate that delivering a COVID-19 vaccine using our HD-MAP technology can potentially be just as effective as the traditional intramuscular vaccine needle injection,” he said.
Do you have an opinion to share? Submit a Letter to the Editor with your name and suburb at Sunshine Coast News via: news@sunshinecoastnews.com.au
The trial will be led by Dr Stephanie Wallace at the USC Clinical Trials clinic at Sippy Downs.
“It’s great to have an opportunity to work with vaccination technology that has been designed and researched here in Australia,” Dr Wallace said.
“The potential of this device to change the way vaccines are delivered around the world is very exciting.”
“This could mean that vaccines could be delivered to remote locations without the need for refrigerated transport.”
“Our community on the Sunshine Coast and at our Moreton Bay clinic have previously shown great interest in this research and have volunteered for the HD-MAP trial in its earlier phase.
“We would encourage them to participate again in this trial with an investigational COVID-19 vaccine,” she said.
The study requires healthy volunteers aged 18 to 50 years old, who are in good general health and have a body mass index within the range of 18-32.
Participants will visit the clinic about seven times during a two-and-a-half-month period.
Those interested in participating can find more information at USC trials.
SUBSCRIBE here now for our FREE news feed, direct to your inbox daily!
